SK Biopharm Q2 Profit Beats Estimates on Xcopri Sales Growth | Korean Stocks
SK Biopharm reported Q2 operating profit of 97.1 billion won, exceeding market expectations, driven by strong US sales of epilepsy drug Xcopri. The South Korean pharmaceutical company announced on the 5th that Q2 revenue reached 247.4 billion won, up 40.3% year-over-year, while operating profit
SK6.17%
LucasBennett·9m ago



